- Home
- TNXP vs FATE Comparison
TNXP vs FATE Comparison
Compare TNXP & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- FATE
- Stock Information
- Founded
- TNXP 2007
- FATE 2007
- Country
- TNXP United States
- FATE United States
- Employees
- TNXP N/A
- FATE N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNXP Health Care
- FATE Health Care
- Exchange
- TNXP Nasdaq
- FATE Nasdaq
- Market Cap
- TNXP 207.5M
- FATE 177.7M
- IPO Year
- TNXP N/A
- FATE 2013
- Fundamental
- Price
- TNXP $33.33
- FATE $1.18
- Analyst Decision
- TNXP Strong Buy
- FATE Hold
- Analyst Count
- TNXP 2
- FATE 7
- Target Price
- TNXP $585.00
- FATE $3.83
- AVG Volume (30 Days)
- TNXP 1.1M
- FATE 2.0M
- Earning Date
- TNXP 08-15-2025
- FATE 08-12-2025
- Dividend Yield
- TNXP N/A
- FATE N/A
- EPS Growth
- TNXP N/A
- FATE N/A
- EPS
- TNXP N/A
- FATE N/A
- Revenue
- TNXP $10,041,000.00
- FATE $13,335,000.00
- Revenue This Year
- TNXP $11.66
- FATE N/A
- Revenue Next Year
- TNXP $793.18
- FATE N/A
- P/E Ratio
- TNXP N/A
- FATE N/A
- Revenue Growth
- TNXP N/A
- FATE 105.85
- 52 Week Low
- TNXP $6.76
- FATE $0.66
- 52 Week High
- TNXP $137.25
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- TNXP 52.50
- FATE 46.59
- Support Level
- TNXP $33.41
- FATE $1.16
- Resistance Level
- TNXP $37.42
- FATE $1.32
- Average True Range (ATR)
- TNXP 3.48
- FATE 0.16
- MACD
- TNXP -1.12
- FATE -0.04
- Stochastic Oscillator
- TNXP 33.66
- FATE 8.33
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.